Methotrexate 59-05-2 Antimetabolite Pharmaceutical Intermediate Research Oncology Use

Methotrexate (CAS 59-05-2) is a folic acid antagonist belonging to the antimetabolite class. It is widely used in pharmaceutical research and biochemical studies due to its ability to inhibit dihydrofolate reductase, thereby affecting DNA synthesis and cell proliferation.

It is commonly applied in oncology research, autoimmune mechanism studies, and pharmaceutical formulation development.

• Folic acid antagonist structure
• High biological activity
• Strong enzyme inhibition effect
• Stable crystalline compound
• Suitable pharmaceutical intermediate
• High purity research grade
• Well studied mechanism of action
• Consistent chemical performance

• Oncology research studies
• Anticancer research systems
• Autoimmune disease research
• Pharmaceutical intermediate synthesis
• Cell biology research systems
• Clinical formulation development
• Laboratory biochemical studies
• Enzyme inhibition studies

Methotrexate is a structural analogue of folic acid that competitively inhibits dihydrofolate reductase. This inhibition disrupts nucleotide synthesis and DNA replication, making it a key compound in biochemical and pharmaceutical research.

• Well-characterized mechanism of action
• High research value in oncology
• Stable crystalline structure
• Suitable for laboratory use
• Consistent analytical performance
• Widely referenced in biochemical studies

Store in a tightly sealed container in a cool, dry place. Protect from light and moisture to maintain stability and chemical integrity.

• 1 g / 10 g research vials
• 100 g / 500 g sealed foil bags
• Custom bulk packaging available

Each batch is analyzed by HPLC for purity, moisture content, and impurity profile to ensure consistent quality suitable for research applications.